GH1 and congestive heart failure: The first was non-randomized, and included seven patients (55 ± 9 years of age) with congestive heart failure and LV dysfunction; they were assessed at the baseline, three months after GH treatment, and three months after cessation of treatment, whereas a control group was absent.